The Food and Drug Administration (FDA) has been exceptionally busy in November 2023, approving six new treatments in the oncology space — and CURE® covered ...

Velcade (bortezomib), Rituxan (rituximab), cyclophosphamide, doxorubicin hydrochloride, prednisone and cytarabine hydrochloride (VR-CAP) generated improved ...

I am not a nice person. There are some who would even call me a cold hearted b****. A friend once told me he wouldn’t want to meet me in a dark alley and he ...

Datopotamab deruxtecan (Dato-DXd) elicited encouraging responses in patients with heavily pretreated non-small cell lung cancer (NSCLC) harboring actionable ...

You’re reading the fifth article in our Health Inequalities Series. It’s part of our ongoing investigation into how inequalities impact every aspect of ...

Pelabresib, an investigational BET inhibitor, when administered in combination with JAK inhibitor Jakafi (ruxolitinib), has been shown to reduce spleen ...

The treatment combination of Welireg (belzutifan) and Cabometyx (cabozantinib) demonstrated durable anti-tumor activity in patients with clear cell renal ...

During my first year of medical school, we spent a week learning about cancer-causing genetic mutations. Unfortunately, this topic was something I was ...

Today, all eyes were on the Chancellor as he set out the economic forecast and announced fiscal measures and public spending in the autumn statement. ...

How could anyone be thankful for a devastating, life-altering disease? Though challenging and inconceivable, it is possible. Learn about how I managed to ...